Profile data is unavailable for this security.
About the company
Oryzon Genomics SA, is a Spain-based clinical phase biopharmaceutical company, which discovers and develops drugs based on epigenetics for the treatment of oncological and neurological diseases. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The Company also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.
- Revenue in EUR (TTM)0.00
- Net income in EUR-2.65m
- Incorporated2000
- Employees47.00
- LocationOryzon Genomics SASant Ferran 74CORNELLA DE LLOBREGAT 08940SpainESP
- Phone+34 935151313
- Fax+34 933774028
- Websitehttps://www.oryzon.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BioInvent International AB | 23.10m | -30.56m | 159.86m | 124.00 | -- | 2.48 | -- | 6.92 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Thor Medical ASA | 8.83k | -5.20m | 165.43m | 13.00 | -- | 3.90 | -- | 18,730.67 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| Devyser Diagnostics AB | 22.91m | -2.38m | 165.59m | 115.00 | -- | 5.15 | 1,253.78 | 7.23 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
| Sensorion SA | 0.00 | -28.09m | 174.57m | 68.00 | -- | 1.79 | -- | -- | -0.0931 | -0.0931 | 0.00 | 0.1895 | 0.00 | -- | -- | 0.00 | -32.12 | -34.53 | -38.36 | -43.50 | -- | -- | -- | -- | -- | -- | 0.0265 | -- | -- | -- | -17.72 | -- | 98.90 | -- |
| MindMaze Therapeutics Holding SA | 4.44m | -18.66m | 185.71m | 31.00 | -- | 0.4108 | -- | 41.84 | -1.36 | -1.36 | 0.3231 | 2.59 | 0.0682 | 2.49 | 2.75 | 130,774.20 | -28.66 | -33.04 | -30.87 | -35.76 | 60.24 | -- | -420.33 | -874.66 | 3.80 | -49.62 | 0.055 | -- | 39.52 | -- | 82.56 | -- | -- | -- |
| Egetis Therapeutics AB (publ) | 5.23m | -31.45m | 187.89m | 40.00 | -- | 6.52 | -- | 35.95 | -0.9376 | -0.9376 | 0.1554 | 0.7725 | 0.0945 | 45.53 | 1.93 | 1,582,857.00 | -56.85 | -36.53 | -87.92 | -41.52 | 30.14 | 81.16 | -601.62 | -558.74 | 0.7971 | -45.06 | 0.249 | -- | -19.97 | -11.00 | -5.11 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -10.69m | 190.64m | 5.00 | -- | 9.87 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Selvita SA | 88.76m | -687.03k | 191.73m | 434.00 | -- | 2.55 | 15.29 | 2.16 | -0.1577 | -0.1577 | 20.37 | 17.23 | 0.5983 | 8.96 | 4.97 | 398,187.40 | -0.4629 | 5.76 | -0.5715 | 7.33 | 80.27 | 80.65 | -0.7737 | 8.57 | 0.8823 | 0.7538 | 0.3757 | -- | -1.73 | -- | -108.73 | -- | -- | -- |
| Diamyd Medical AB | 32.83k | -17.21m | 214.14m | 41.00 | -- | 10.06 | -- | 6,522.71 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
| Cellectis SA | 69.55m | -29.79m | 223.51m | 224.00 | -- | 2.65 | -- | 3.21 | -0.2969 | -0.2969 | 0.6915 | 1.17 | 0.2234 | -- | 8.58 | 310,498.60 | -9.57 | -21.50 | -16.65 | -29.24 | -- | -32.79 | -42.82 | -220.86 | -- | -3.13 | 0.5013 | -- | 435.37 | 16.44 | 66.41 | -- | -21.58 | -- |
| Transgene SA | 7.24m | -36.78m | 230.87m | 147.00 | -- | -- | -- | 31.89 | -0.1456 | -0.1456 | 0.0618 | -0.0272 | 0.1578 | -- | 8.72 | 43,872.73 | -80.19 | -33.32 | -186.71 | -40.55 | -- | -- | -508.10 | -251.37 | -- | -17.28 | 1.13 | -- | -20.34 | -14.48 | -52.15 | -- | 12.68 | -- |
| Oryzon Genomics SA | 0.00 | -2.65m | 244.86m | 47.00 | -- | 2.04 | -- | -- | -0.0406 | -0.0406 | 0.00 | 1.51 | 0.00 | 95.26 | -- | 0.00 | -2.08 | -3.91 | -2.37 | -4.48 | -- | -- | -- | -- | 2.13 | -8.64 | 0.0725 | -- | -- | -- | -9.32 | -- | -4.26 | -- |
| Eurobio Scientific SA | 162.09m | 2.36m | 244.95m | 380.00 | 101.88 | 1.33 | 13.75 | 1.51 | 0.2346 | 0.2346 | 15.76 | 18.03 | 0.5651 | 1.62 | 5.21 | 497,196.30 | 0.8231 | 14.00 | 1.02 | 17.37 | 23.69 | 51.40 | 1.46 | 20.70 | 1.25 | 1.72 | 0.0845 | 0.00 | 18.89 | 21.21 | -17.31 | 4.86 | 15.38 | -- |
| Vicore Pharma Holding AB | 801.99k | -40.04m | 276.22m | 36.00 | -- | 3.06 | -- | 344.41 | -1.85 | -1.85 | 0.0371 | 3.40 | 0.0134 | -- | 2.04 | 293,137.90 | -66.65 | -49.13 | -71.78 | -54.58 | -- | -- | -4,992.90 | -1,107.81 | -- | -35.34 | 0.00 | -- | -- | -- | 45.77 | -- | -- | -- |
| Avacta Group Plc | -12.73m | -37.98m | 295.69m | 151.00 | -- | 1,599.37 | -- | -- | -0.0891 | -0.1579 | -0.0298 | 0.0004 | -0.1872 | -- | -- | -73,456.95 | -55.83 | -43.48 | -129.38 | -78.27 | -- | 63.54 | -- | -781.44 | 0.7883 | -0.4837 | 0.993 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Saniona AB | 70.11m | 54.10m | 323.59m | 31.00 | 5.41 | 4.97 | 5.91 | 4.62 | 4.60 | 4.60 | 5.98 | 5.00 | 1.75 | -- | 121.92 | 33,782,040.00 | 135.23 | -38.47 | 170.81 | -45.71 | 90.13 | -55.15 | 77.16 | -156.43 | -- | -- | 0.0004 | -- | 1,887.36 | 115.50 | 296.96 | -- | -48.69 | -- |
Data as of Feb 13 2026. Currency figures normalised to Oryzon Genomics SA's reporting currency: Euro EUR
2.77%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Heights Capital Management, Inc.as of 01 Aug 2025 | 1.70m | 2.12% |
| Gescooperativo SA SGIICas of 31 Dec 2025 | 216.68k | 0.27% |
| Dimensional Fund Advisors LPas of 08 Jan 2026 | 101.45k | 0.13% |
| Market Portfolio Asset Management SGIIC SAas of 31 Dec 2025 | 97.12k | 0.12% |
| Santander Private Banking Gestion SA SGIICas of 30 Jun 2025 | 50.00k | 0.06% |
| Gesiuris Asset Management SGIIC SAas of 31 Dec 2025 | 21.80k | 0.03% |
| Andbank Asset Management Luxembourg SAas of 30 Jun 2025 | 15.00k | 0.02% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 12.02k | 0.02% |
| Gesti�n de Patrimonios Mobiliarios AV SAas of 31 Dec 2025 | 4.00k | 0.01% |
| Andbank Wealth Management SGIIC SAUas of 31 Dec 2025 | 199.00 | 0.00% |
More ▼
Data from 30 Sep 2025 - 04 Feb 2026Source: FactSet Research Systems Inc.
